Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Baseline Characteristics of the Patients (N = 60)

From: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Demographic profile:

Liraglutide, N = 30

Dulaglutide, N = 30

P value

Male, n (%)

28(46.7%)

13 (43.3%)

15 (50%)

0.605

Female, n (%)

32 (53.3%)

17 (56.7%)

15 (50%)

 

Age(years), Mean ± SEM

47.75 ± 1.22

47.33 ± 1.91

48.17 ± 1.55

0.736

Height (centimeters), Mean ± SEM

161.53 ± 1.2

159.97 ± 1.52

163.10 ± 1.83

0.193

Body weight(Kg), Mean ± SEM

88.3 ± 1.68

89.43 ± 2.60

87.17 ± 2.16

0.506

Diabetes duration, (years), Mean ± SEM

6.07 ± 0.70

5.55 ± 0.94

6.59 ± 1.03

0.46

SBP(mmHg), Mean ± SEM

136.07 ± 1.84

137.83 ± 2.50

134.30 ± 2.71

0.342

DBP(mmHg), Mean ± SEM

82.1 ± 1.15

83.47 ± 1.58

80.73 ± 1.64

0.236

BMI(kg/m2), Mean ± SEM

34.99 ± 5.66

34.92 ± 0.86

32.84 ± 0.77

0.078

BMI – 25 -29.9

10 (16.67%)

   

BMI - 30-34.9

30 (50%)

   

BMI - 35-39.9

12 (20%)

   

BMI - ≥40

8 (13.33%)

   

FPG(mg/dL), Mean ± SEM

167.83 ± 7.04

160.13 ± 8.17

175.53 ± 11.45

0.278

HbA1c(%), Mean ± SEM

8.46 ± 0.17

8.49 ± 0.26

8.43 ± 0.21

0.847

On Metformin, n (%)

60 (100%)

30 (100%)

30 (100%)

1.00

On SGLT-2is, n (%)

60 (100%)

30 (100%)

30 (100%)

1.00